The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges
18:41
18:41
Play later
Play later
Lists
Like
Liked
18:41
This week's VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually. You hear from experts Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, who discusses key hemophilia clinical trials in 2024, Rad…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more
17:29
17:29
Play later
Play later
Lists
Like
Liked
17:29
In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal Transducer and Activator of Transcription (STAT) and Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) are critical mediators in this process, where dysregulated signaling leads to aberrant hematopoiesis and t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs
11:58
11:58
Play later
Play later
Lists
Like
Liked
11:58
Today’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in si…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
16:00
16:00
Play later
Play later
Lists
Like
Liked
16:00
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in anemia and thrombocytopenia. There are many unmet treatment needs that remain in this space. This week’s podcast features a discussion from the International Workshop on Myelodys…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
12:13
12:13
Play later
Play later
Lists
Like
Liked
12:13
The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024. Tune in as Man…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Novel developments in lower-risk MDS & important practical considerations when treating patients
51:42
51:42
Play later
Play later
Lists
Like
Liked
51:42
In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients. You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
16:18
16:18
Play later
Play later
Lists
Like
Liked
16:18
BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Me…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
12:10
12:10
Play later
Play later
Lists
Like
Liked
12:10
In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospit…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
8:43
8:43
Play later
Play later
Lists
Like
Liked
8:43
Welcome to today's VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field. Join leading experts Mario Nuvolone, MD, PhD, Univers…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
46:31
46:31
Play later
Play later
Lists
Like
Liked
46:31
While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that remains is the treatment of patients following the failure of erythropoiesis-stimulating agents (ESAs). In this podcast, experts Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Valeria Santini, MD, Univers…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
34:39
34:39
Play later
Play later
Lists
Like
Liked
34:39
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
12:34
12:34
Play later
Play later
Lists
Like
Liked
12:34
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immu…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
27:24
27:24
Play later
Play later
Lists
Like
Liked
27:24
The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field. In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
11:43
11:43
Play later
Play later
Lists
Like
Liked
11:43
Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients. Today's VJHemOnc podcast features experts Mary Frances McM…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
22:50
22:50
Play later
Play later
Lists
Like
Liked
22:50
Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week's VJHemOnc podcast, we'll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD. Tune in as experts Moham…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
43:51
43:51
Play later
Play later
Lists
Like
Liked
43:51
In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting the value of collaboration between specialists when treating patients with hematological malignancies. Furthermore, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines aim to help he…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
22:22
22:22
Play later
Play later
Lists
Like
Liked
22:22
Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field. In this week's podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
13:02
13:02
Play later
Play later
Lists
Like
Liked
13:02
Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies, indicating early stages of blood disorders that may progress to more serious conditions such as leukemia or myelodysplastic syndromes (MDS). In this podcast, Uma Borate, MD, The Oh…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
9:39
9:39
Play later
Play later
Lists
Like
Liked
9:39
Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the blood. MBL is considered a precursor condition to chronic lymphocytic leukemia (CLL); however, not all cases of MBL progress to CLL, and many individuals with MBL do not require treatment. In this podcast, Stephen Ansel…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
13:00
13:00
Play later
Play later
Lists
Like
Liked
13:00
The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies explor…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
33:31
33:31
Play later
Play later
Lists
Like
Liked
33:31
While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due to the highly varied presentation of this disease. As clinicians and researchers work to improve outcomes for patients, there is increasing importance being placed on the role of the multidisciplinary team in treating the…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
13:02
13:02
Play later
Play later
Lists
Like
Liked
13:02
Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding the use of these agents. One ongoing challenge is the prevention and management of CAR-T-related toxicities, including immune effector cell-associated hematotoxicity (ICAHT), as well as how to im…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
12:58
12:58
Play later
Play later
Lists
Like
Liked
12:58
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today's episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discu…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
12:10
12:10
Play later
Play later
Lists
Like
Liked
12:10
The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT3 inhibitors, IDH inhibitors, and menin inhibitors. Menin inhibitors are currently being explored in several clinical trials, both as monotherapy and in combination with other agents. In this podcast, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
18:16
18:16
Play later
Play later
Lists
Like
Liked
18:16
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS; HR-MDS). Treatment and management strategies vary for LR-MDS versus HR-MDS, and a number of challenges remain in the field. In this podcast, you will hear from leading experts who discuss several t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
12:21
12:21
Play later
Play later
Lists
Like
Liked
12:21
In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several agents being evaluated in clinical trials, the future looks promising for patients. Despite these advances, there are challenges and unmet needs which remain, and both clinicians and researchers are working to addre…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates, challenges and novel agents being explored in BPDCN
9:49
9:49
Play later
Play later
Lists
Like
Liked
9:49
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain in the diagnosis, treatment and management of this disease, with a lack of clinical trials in the field. However, clinicians and researchers are working to improve upon these unmet needs, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
18:18
18:18
Play later
Play later
Lists
Like
Liked
18:18
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options, with associated benefits and challenges. Several ongoing clinical trials in the field are investigating potential treatment approaches and addressing many unanswered questions. In this podcast, Moham…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
11:04
11:04
Play later
Play later
Lists
Like
Liked
11:04
In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recently approved gene therapies. There are several ongoing trials evaluating the safety of these agents in patients, with promising results being demonstrated. In this podcast, leading experts Rabi Hanna, M…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
10:29
10:29
Play later
Play later
Lists
Like
Liked
10:29
In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis and risk stratification remain a challenge, clinicians and researchers are working to improve upon these. Furthermore, novel immunotherapies are being explored in the field, providing hope for patients…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
17:12
17:12
Play later
Play later
Lists
Like
Liked
17:12
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed in recent years. Several clinical trials are exploring the safety and efficacy of novel agents and combinations, with promising advances being made. At the 65th ASH Annu…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwNHL 2023 Session V: Expanding the CAR platform in NHL
10:59
10:59
Play later
Play later
Lists
Like
Liked
10:59
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
20:50
20:50
Play later
Play later
Lists
Like
Liked
20:50
The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who shared the latest updates in the treatment and management of CLL. Tune in as we share some key highlights from this year's meeting. In this podcast, a variety of topics are covered, including the role …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
15:34
15:34
Play later
Play later
Lists
Like
Liked
15:34
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
12:23
12:23
Play later
Play later
Lists
Like
Liked
12:23
In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in this disease. Early and accurate diagnosis present a key challenge, and both clinicians and researchers are investigating novel strategies with the aim of improving outcomes for patients. In this podcast, Angela Di…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
16:08
16:08
Play later
Play later
Lists
Like
Liked
16:08
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
12:57
12:57
Play later
Play later
Lists
Like
Liked
12:57
The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diag…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
14:37
14:37
Play later
Play later
Lists
Like
Liked
14:37
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma
13:52
13:52
Play later
Play later
Lists
Like
Liked
13:52
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwAL 2023 Session IV: transplantation and immunotherapies in AML: improving patient outcomes
14:41
14:41
Play later
Play later
Lists
Like
Liked
14:41
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeti…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Classifying frailty and approaching elderly patients with lymphoma
11:11
11:11
Play later
Play later
Lists
Like
Liked
11:11
While the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several challenges associated with treating elderly patients in these disease settings. The presence of comorbidities, as well as the risk of treatment-related toxicities, makes the treatment of elderly patients an important area…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
19:04
19:04
Play later
Play later
Lists
Like
Liked
19:04
The treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are being conducted with the goal of improving the understanding of this disease. Furthermore, there have been recent updates to classification systems for MDS, including the Molecular International Prognostic Sco…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwAL 2023 Session III: The relevance of TP53 mutation in AML
9:55
9:55
Play later
Play later
Lists
Like
Liked
9:55
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeti…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
28:06
28:06
Play later
Play later
Lists
Like
Liked
28:06
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeti…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
18:04
18:04
Play later
Play later
Lists
Like
Liked
18:04
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeti…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
10:51
10:51
Play later
Play later
Lists
Like
Liked
10:51
Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of MRD testing has increased in recent years. MRD can indicate the depth of response to treatment as well as patient outcomes, leading to suggestions of using MRD status to guide the treatment of patients with myeloma. In this pod…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
9:17
9:17
Play later
Play later
Lists
Like
Liked
9:17
The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent years, the introduction of immunotherapies including CAR-T cells and bispecific antibodies has provided hope for several patients. While both CAR-T cells and bispecific antibodies have their benefits, there are s…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
10:05
10:05
Play later
Play later
Lists
Like
Liked
10:05
Myelodysplastic syndromes (MDS) represent a heterogeneic group of disorders which remain a challenge to diagnose and treat. In recent years, there has been an increased interest in understanding various pre-MDS states, including idiopathic cytopenia of unknown significance (ICUS), clonal hematopoiesis of indeterminate potential (CHIP), and clonal c…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
8:17
8:17
Play later
Play later
Lists
Like
Liked
8:17
Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including ASXL1, EZH2, and TP53, are involved in progression to MPN-AP/BP, and there are a number of challenges with treating patients who progress to this stage. In this podcast, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
7:07
7:07
Play later
Play later
Lists
Like
Liked
7:07
Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory (R/R) disease. While both of these therapies offer benefits to patients, there are challenges to address regarding the optimal sequencing of these agents. In this podcast, experts Salomon Manie…
…
continue reading